Food, Global Health 2 min

Impact of an antidiabetic drug on male fertility after foetal exposure in mice

PRESS RELEASE - Metformin is a drug used to treat diabetes but can also be prescribed during pregnancy to patients suffering from gestational diabetes or obesity. A research team from INRAE, Inserm, the international agency for research on cancer and the University of New South Wales (Australia) studied the impact of foetal exposure to metformin in mice during pregnancy. Their findings, published in the October 18 issue of Frontiers in Endocrinology, show that foetal exposure to this drug induces decreased fertility and increased fat accumulation, but only in males. These results in mice have not yet been confirmed in humans.

Published on 18 October 2021

illustration Impact of an antidiabetic drug on male fertility after foetal exposure in mice
© pxfuel

Metformin is a drug used to regulate glucose levels in the blood and is prescribed as a treatment for type 2 diabetes. It can also be prescribed to patients during pregnancy who suffer from gestational diabetes or obesity. However, the consequences of foetal exposure to metformin on the fertility of offspring are poorly documented. That is why researchers have turned their attention to how the drug affects the fertility of offspring when administered to gestating mice.

A drop in fertility among male offspring

Researchers at INRAE had already shown that exposure to metformin in mice during the embryonic stages slows testicular growth and leads to a drop in the production of testosterone in male foetuses (cf references). In this new study, 12 female mice were given metaformin in drinking water for the duration of pregnancy in quantities equivalent to those given to humans for the treatment of diabetes. Another control group of 8 mice was given water with no added metformin. The study showed that metformin does not accumulate in foetal tissue but passes into the bloodstream and the amniotic fluid that surrounds the foetus during pregnancy. This exposure upsets the metabolism of the foetus and provokes a slowdown in testicular growth in males. The researchers also observed that male mice exposed to metformin during pregnancy weighed more than those of the control group and accumulated twice as much fat as males from the control group.

To study the consequences on fertility, male and female offspring from female mice exposed to metformin during gestation were mated with mice from the control group. Male mice who had been exposed to metformin were less fertile than those from the control group, siring litters 30% smaller (5.5 pups on average per litter for males exposed to metformin v. 8 pups per litter from males from the control group). To understand the cause of this decrease in fertility, the scientists studied the sperm produced by the male mice. They observed a lower sperm count in the males exposed to metformin. They also observed higher levels of malformations of sperm cell heads (25% in males exposed v. 15% in the control group), higher rates of sperm DNA damage (55% in exposed males v. 25% in males from the control group), and greater genomic DNA methylation associated with TET proteins, an epigenetic marker influencing gene expression.

Perturbations in metabolism during the foetal stage, here induced by metformin, could affect fertility in adulthood, but these results have yet to be confirmed in humans.  With this in mind, a cohort study carried out by the faculty of medicine of the Norwegian University of Science and Technology is currently underway to identify the effects on humans. Studies on animals will also continue, notably to see if the effects persist over several generations.


Mélanie C. Faure, Rita Khouiery, Jusal Quanico, Herve Acloque, Marie-justine Guerquin, Michael Bertoldo, Claire Chevaleyre, Christelle Rame, Isabelle Fournier, Michel Salzet, Joelle Dupont, Pascal Froment, In utero exposure to metformin reduces the fertility of male offspring in adulthood, Frontiers in Endocrinology 18 October 2021 |

P Tartarin , D Moison, E Guibert, J Dupont, R Habert, V Rouiller-Fabre, N Frydman, S Pozzi, R Frydman, C Lecureuil, P Froment, Metformin exposure affects human and mouse fetal testicular cells, Human Reproduction, Volume 27, Issue 11, November 2012, Pages 3304–3314,

INRAE press office

Scientific contact

Pascal Froment Physiology of Reproduction and Behaviour Joint Research Unit, INRAE, CNRS, University of Tours, IFCE


Learn more

Food, Global Health

Artificial sweeteners: certain adverse metabolic effects revealed in a preclinical model

PRESS RELEASE- INRA researchers, in collaboration with the University of Adelaide, Australia, studied the effects that a widely used artificial sweetener blend, i.e. acesulfame K-sucralose, has on metabolism. For the first time, they revealed – in animals – an increase in glucose absorption, particularly in the brain and fatty tissues, indicating certain undesirable effects on metabolism and insulin sensitivity. These results were published in the 24 July 2019 edition of the European Journal of Nuclear Medicine and Molecular Imaging.

12 December 2019

Food, Global Health

Diabetes and obesity: the disappearance of a glucose detector in the abdomen

PRESS RELEASE - The continuous detection of blood glucose is vital for anticipating hypoglycaemia and limiting hyperglycaemia, both of which are harmful, particularly in diabetes. Two sensors exist in mammals; one in the brain and the other in the abdomen. Thanks to an innovative imaging methodology, INRAE and the University of Adelaide (Australia) have, for the first time, succeeded in quantifying the activity of the abdominal glucose sensor in animals and humans. Their results, published in a series of three articles, demonstrate the disappearance of this sensor in obese patients, and open new therapeutic perspectives to prevent the harmful consequences of obesity eliciting this sensor’s restoration.

13 November 2020

Food, Global Health

New prebiotics: benefits without the downsides?

PRESS RELEASE - Prebiotics are currently a preferred treatment for certain metabolic disorders, as they can restore the balance of dysfunctional gut microbiota, and improve the body’s metabolism. However, these substances have to be used at high doses, which can result in patients experiencing bloating and flatulence. A research group led by Matteo Serino, Inserm researcher at the Digestive Health Research Institute (Inserm/INRA/ENVT/UT3 Paul Sabatier), has recently shown three plant extracts to have prebiotic effects in obese/diabetic mice, with a shorter duration of treatment and at lower doses to the prebiotics currently in use. For Matteo Serino, this raises the question: do we need to reconsider the protocol for prebiotic administration? These results have been published in Molecular Nutrition & Food Research.

12 December 2019